Zepbound 2.5mg 4 Pens

Subscription Plan
Regular price ¥29,980

※ Our store Luxora is currently partnered with Elife (eLife Inc.), which operates the online medical consultation and prescription service platform “elife.”
Luxora is responsible only for sales-related tasks such as orders, cancellations, product changes, and refunds.
All services related to consultations, prescriptions, and product delivery are handled directly by Elife.


Start Your Zepbound Treatment Today!

  • Now available on elife!

  • A once-weekly injection designed to support long-term weight management

  • Combines GLP-1 and GIP to help suppress appetite and regulate blood sugar levels

  • Convenient pre-filled, single-use pen-type injection that fits your schedule

  • Easy to use at home with online medical guidance

Full refund guaranteed if the doctor decides not to prescribe
Online consultation & home delivery make it simple and stress-free
Ideal for those who want to continue until results are felt

What is Zepbound?

Zepbound is the first and only FDA-approved treatment for chronic weight management that combines both a GLP-1 receptor agonist and a GIP receptor agonist.

By suppressing appetite, prolonging satiety, and supporting metabolic health, Zepbound provides a precise and convenient treatment option for sustainable weight management with just a once-weekly injection.

※ Delivered via refrigerated shipping at no additional cost.


Clinical Evidence

In studies using tirzepatide, the active ingredient in Zepbound, significant weight reduction was observed compared to baseline weight after 52 weeks (12 months) of treatment starting at 2.5 mg:

  • Up to 5 mg (by Week 5): Average weight loss of 5.8 kg

  • Up to 10 mg (with 2.5 mg increases every 4 weeks): Average weight loss of 8.5 kg

  • Up to 15 mg (with 2.5 mg increases every 4 weeks): Average weight loss of 10.7 kg

This demonstrates Zepbound’s clinically proven effectiveness for sustained weight reduction.

How to Use

  • Inject once weekly, on the same day of the week, into fatty areas of the abdomen.

  • Do not inject into muscle or veins.

Usage flow:

  1. Preparation: Clean the injection site.

  2. Needle check: Confirm that the needle is securely attached.

  3. Injection: When completed, you will hear two “click” sounds.


Main Side Effects & Prevention

Gastrointestinal discomfort

  • Avoid foods that are hard to digest or greasy, as they may worsen discomfort.

  • Stomach medicine or anti-nausea medication can be effective.

  • Elife offers a support set for side effects. Please contact customer support if desired.

Hypoglycemia (low blood sugar)

  • Avoid excessive dietary restrictions.

  • Carry glucose tablets, candy, or sugar-containing foods during treatment.

  • If symptoms occur, consume them immediately.

Other common side effects: nausea, heartburn, low blood sugar, constipation, diarrhea.
A GLP-1 side effect relief set is also available at Elife—please request this during your consultation if needed.

[Medication Information Page]


📱 Medication Access (Requires Online Consultation)

Flow of Use:

  1. Apply for the Zepbound subscription ticket (with first-month discount) on this page.

  2. You will receive an email with online consultation guidance and a promo code.

  3. Click the link in the email to book a free online medical counseling session with Elife.
    (Be sure to register with the same email address that received the coupon.)

  4. After the consultation, if a prescription is approved, your medication will be shipped directly to your home.
    (If a prescription cannot be issued due to medical judgment, you will receive a full refund.)

※ This treatment is self-funded (not covered by insurance).

Usage Instructions

Remove the Zepbound pen from the refrigerator and check the following before use
Subcutaneous injections are administered once a week on a fixed day of the week. The injection site is the abdomen (right and left side of the abdomen or lower abdomen at least 5 cm away from the navel).

The Effect
  • Weekly injections are OK.Easy to incorporate into daily life and easy to sustain
  • Appetite suppression + fat burning W approachDual agonist" that simultaneously acts on two hormone receptors: GLP-1 and GIP
  • Efficiently reduce fat without losing muscleUnlike conventional diets, they are less likely to rebound.
  • Approx. 20% reduction in body weight in U.S. clinical trialshas been confirmed (SURMOUNT study).
Main Ingredients

tirzepatide stimulates two hormone receptors.

  • GLP-1 (glucagon-like peptide-1): Suppresses appetite, slows stomach movement to make it easier to feel full after a small amount, and lowers blood sugar by stimulating insulin secretion.
  • GIP (glucose-dependent insulin secretion-stimulating polypeptide): It further enhances insulin secretion and efficiently supports weight loss by acting on adipose tissue and metabolism.
All Ingredients
Precautions for use and storage
Zepbound 2.5mg 4 Pens
¥29,980
Zepbound 2.5mg 4 Pens

Significant weight loss at maximum dose

In clinical trials, an average weight loss of approximately 22% has been reported after 72 weeks of use of the maximum dose (15 mg) of Zepbound. For example, a person weighing 100 kg can expect to lose approximately 22 kg.

Approaches health risks while suppressing appetite

Zepbound naturally suppresses appetite and promotes satiety through its effects on two intestinal hormones, GLP-1 and GIP. It also improves blood sugar, blood pressure, lipids, etc., and is expected to reduce the risk of lifestyle-related diseases. The key point is not only the appearance, but also the effect of regulating health from within the body.

Sleep apnea (OSA) improvement is also possible

In late 2024, the FDA approved Zepbound for the treatment of moderate to severe sleep apnea (OSA) associated with obesity for the first time . Its effectiveness in improving breathing during sleep, as well as weight loss, will be of great appeal to those who suffer from daily sleep difficulties and health problems.

Zepbound vs. Manjaro

Both contain Eli Lilly's GLP-1 and GIP receptor agonist tirzepatide (tirzepatide). The pharmacologic actions are the same, but the approved uses are different.

  • ZepboundThe "M" in "M" is a combination of "M" and "A":Obesity and weight management The drug was approved by the U.S. FDA in 2023 and in Japan in 2024 for the treatment of After 72 weeks of use in clinical trials, the average Approx. 22% weight loss has been reported to be effective in improving obesity and weight-related complications. It is also a strong appetite suppressant.
  • MounjaroMainly Drugs for Type 2 Diabetes Approved as a Excellent glycemic control and weight loss in diabetic patients. Expected to reduce cardiovascular risk.

Help & FAQs

Need more help? Contact us on LINE.

This is because a certain period of continuity is recommended in order to properly determine the effectiveness of weight loss and its compatibility with your body. In order to provide our patients with responsible medical care, we offer special discount plans in a form that makes it easy for you to experience the benefits.

No. The application must be submitted by the applicant. A doctor's consultation is always required after application. The medication will be shipped after the prescription is confirmed by the consultation.

Yes, of course. Even if you are on the "Firm Continuation Plan," we will promptly cancel your subscription if we detect any side effects that doctors deem to make it difficult for you to continue taking the plan. Patient safety is our top priority.